ArticleMolecules (Basel, Switzerland)2018
The Antitumor Activity of a Lead Thioxanthone is Associated with Alterations in Cholesterol Localization.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Bioactivity of Synthesized Trifluoromethyl Thioxanthone Analogues.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Antifungal Activity of a Library of Aminothioxanthones.Antibiotics (Basel, Switzerland) · 2022Article
- Comparative performance and reusability studies of lipases on syntheses of octyl esters with an economic approach.Bioprocess and biosystems engineering · 2022Article
- An Update on the Anticancer Activity of Xanthone Derivatives: A Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Autophagic Activation and Decrease of Plasma Membrane Cholesterol Contribute to Anticancer Activities in Non-Small Cell Lung Cancer.Molecules (Basel, Switzerland) · 2021Article
- Tetracyclic Thioxanthene Derivatives: Studies on Fluorescence and Antitumor Activity.Molecules (Basel, Switzerland) · 2021Article
- From Natural Products to New Synthetic Small Molecules: A Journey through the World of Xanthones.Molecules (Basel, Switzerland) · 2021Review
- Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9EXCLI journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
The search for novel anticancer small molecules and strategies remains a challenge. Our previous studies have identified TXA1 (1-{[2-(diethylamino)ethyl]amino}-4-propoxy-9H- thioxanthen-9-one) as a hit compound, with in vitro antitumor potential by modulating autophagy and apoptosis in human tumor cell lines. In the present study, the mechanism of action and antitumor potential of the soluble salt of this molecule (TXA1.HCl) was further investigated using in vitro and mouse xenograft tumor models of NSCLC. Our results showed that TXA1.HCl affected steroid biosynthesis, increased RagD expression, and caused abnormal cellular cholesterol localization. In addition, TXA1.HCl treatment presented no toxicity to nude mice and significantly reduced the growth of human NSCLC cells xenografts in mice. Overall, this work provides new insights into the mechanism of action of TXA1, which may be relevant for the development of anticancer therapeutic strategies, which target cholesterol transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.